Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu.

S xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxx Přílohy X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx x platnost x souladu s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku vstoupilo x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Přílohu X xxx rok 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., XX.X., x. r.

vrchní ředitel xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx každoročně xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Xxxxxx je xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx WADA a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx textem xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx pojmy xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx soutěži v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x den předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx do xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, jak xx xxxxxxxxxx x Kodexu.

Specifické x Nespecifické

Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx jiné xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx o xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx nebo použil x jinému xxxxx xxx xx zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Návykové xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx se xxxxxxxxxx xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx veterinární xxxxxxx), xx zakázána stále.

Tato xxxxx zahrnuje xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx zakázány.

S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (estr-4-en-3,17-diol)		•	metyltestosteron
•	19-norandrostenedion (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. andarin, enobosarm (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX FAKTORY, XXXXXXXX XXXXX A XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky x xxxxxx sloučeniny, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (LH),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, nafarelin x triptorelin),

 • xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, např. AOD-9604 x hGH 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx jiné xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x jeho xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) x jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x neselektivní beta-2 xxxxxxxx včetně všech xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 jsou Specifické xxxxx.

Xxxxx xxxxxxxx do xxxx S4.3 a X4.4 jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX RECEPTORU AKTIVINU XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx nebo xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. ACE-031)			- xxxxxxxx xxxxxx xxxxxxxxx (např. xxxxxxxxxxx, propeptid myostatinu)
•	protilátky xxxxx receptoru xxxxxxxx XXX (xxxx. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Desmopresin;

• Probenecid;

a xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x lokální xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx podání xxxxxxxxxxx x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Sportovce xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx podání inhibitoru xxxxxxxxxxxxxx xxxx lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx anestezii), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na xxxx xxxxx navíc k xx, xxxxx xxx xxxx udělena na xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx metody x xxxx třídě jsou Xxxxxxxxxxxx x výjimkou xxxxx v X2.2, xxx xxxx Specifické xxxxxx.

X1. MANIPULACE X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv množství xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx krve xxxx produktů z xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s výjimkou xxxxxxxx xxxxxx nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx xxxxxx porušit xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo xxxx xxxxxx:

Xxxxxx a/nebo úprava Xxxxxx, např. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx vyšetření.

M3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, které xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx jakýmkoliv mechanismem. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx x S6.A, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx látky v xxxx sekci: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- a l-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx látkou.

S6.B: XXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx a xxxx xxxxxxx, např. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx použití (např. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Xxxxxxxxxx látky.

Návykové xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. d- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Specifické xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx zakázané, xxxx.

• x xxxxxx (xxxxx, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx cestou.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního a xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx se používají x rámci výrobcem xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx pouze v xxxxxxxxxxxxx sportech Xxx Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) i Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, akrobatické skoky / X-xxxxx a xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx jazyce
 

¹⁾ katin (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: je xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx koncentraci x xxxx vyšší xxx 150 xxxxxxxxxx x 1 ml.

³⁾ xxxxxxx x metylefedrin: zakázány xxx xxxxxxxxxxx x xxxx vyšší xxx 10 mikrogramů v 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání s xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: tyto látky xxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx předpis x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx netýká derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu